Biote in the News
Learn more about what is happening at Biote and what people are saying.
Biote Announces Participation in ICR Conference 2022
Biote’s management team will participate virtually in the ICR Conference 2021.
READ ARTICLEBiote to be Listed on Nasdaq through a Business Combination with Haymaker Acquisition Corp. III
BioTE Holdings, LLC, (Biote), a high-growth, differentiated medical practice-building business within the hormone optimization space (“Biote”), and Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker”), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing, the combined company’s Class A common stock is expected to be traded on the Nasdaq Stock Market (“Nasdaq”) under the symbol “BTMD.”
CONTINUE READINGBreast Cancer Study by Dr. Gary Donovitz Featured in NurseZone Blog
Study results showing that women who took testosterone via hormone pellets as part of bioidentical hormone replacement therapy (BHRT) had a 35.5% lower incidence of invasive breast cancer were cited in a recent NurseZone article. Read the article, “9 Advances in Breast Cancer Treatment,” to learn more about several recent, critical advances in this area.
READ ARTICLEBiote Recognized as 50-Fastest-Growing Women-Owned/Led Companies of 2021
Biote has been recognized as one of the 50 Fastest Women-Owned/Led Companies by The Woman Presidents’ Organization (WPO), in collaboration with JPMorgan Chase Commercial Banking, in their 14th annual ranking.
CONTINUE READINGDr. Mark Cone & Dana Jacoby Elected to Biote’s Board of Directors
Biote announced the appointments of Dr. Mark Cone and Dana Jacoby to the company’s Board of Directors. Cone and Jacoby bring six decades of combined experience in healthcare practice and business leadership to the company’s Board.
CONTINUE READINGStudy: Testosterone Pellet Therapy Reduces Breast Cancer Incidence in Women
A new study published by Biote founder Dr. Gary Donovitz, FACOG, and Mandy Cotten, DNP, APRN, FNP-C found that women who took testosterone via hormone pellets as part of bioidentical hormone replacement therapy (BHRT) had a 35.5% lower incidence of invasive breast cancer.
CONTINUE READINGLargest Real-World Study of Bioabsorbable Testosterone Pellets in Men and Women Shows Low Complication Rates Over 7 Years and 1.2 Million Implants
Delivering testosterone via bioabsorbable pellets inserted under the skin is a low-risk approach to long-term hormone therapy for women and men, according to peer-reviewed data that Dr. Gary Donovitz, Biote founder, has published in the journal “Therapeutic Advances in Endocrinology and Metabolism” (TAEM).
CONTINUE READING5 Things You Should Do To Optimize Your Wellness After Retirement
As part of my series about the “5 Things You Should Do to Optimize Your Wellness After Retirement,” I had the pleasure of interviewing Cory Rice. Cory graduated from Baylor University with a bachelor’s degree in forensic science and then completed medical school at the Arizona College of Osteopathic Medicine in Glendale, Arizona.
CONTINUE READING
Dr. Gary Donovitz Explains Hormone Optimization on Dr. Drew
Biote Founder Dr. Gary Donovitz visits the Dose of Dr. Drew podcast to discuss the benefits of the Biote Method of hormone optimization.
PLAY VIDEO
Women In Wellness: “Things move very slowly in healthcare; You have to ask for what you need” With Terry Weber of Biote
Things move very slowly in healthcare. You have to ask for what you need. You must show a clear vision and build coalitions across special interests and competitors. This will be the only way to affect real change in healthcare.
CONTINUE READING